Pulmonary hypertension (PH) has a high mortality rate if untreated. Unfortunately, the disease is not consistently diagnosed or treated across the United States. To improve the diagnosis and care of ...

MILAN — Sotatercept, a first-in-class activin signaling inhibitor, is currently under scrutiny as a potential game-changer in the treatment of pulmonary arterial hypertension (PAH). Data unveiled at ...

Please provide your email address to receive an email when new articles are posted on . There is generally high awareness surrounding the 2022 guidelines for pulmonary hypertension, although some gaps ...

The model has potential to assist integrated delivery network health care providers through early identification of patients with pulmonary arterial hypertension (PAH), a rare but fast-progressing ...

To assess how a patient with pulmonary arterial hypertension (PAH) is faring on therapy, look at the right heart, said Anjali Vaidya, MD, in a presentation at the Annual Meeting of the American ...

In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently diagnosed in patients with cardio-pulmonary comorbidities, which poses ...

Please provide your email address to receive an email when new articles are posted on . In patients with pulmonary arterial hypertension, many initially receive just one drug of the combination ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries in your lungs. It happens when these arteries become narrow or blocked, making it harder for blood to flow ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that go from your heart to your lungs. It happens when these arteries become narrow or blocked, making it harder ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...